Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HighTide Closes $107 Million Round for Metabolic/Digestive Disease Candidates

publication date: Jan 5, 2023

HighTide Therapeutics, a Shenzhen-Maryland biopharma, closed a $107 Million C/C+ funding from China investors to support its candidates for metabolic and digestive diseases. The company’s lead candidate, HTD1801, is a first-in-class new molecular entity that is being tested in Phase II trials for type 2 diabetes, nonalcoholic steatohepatitis and primary sclerosing cholangitis. The C/C+ Round was led by the TCM Healthcare Fund of Guangdong, which is managed by China Development Bank Capital, and included Yuexiu Fund and Yuthai Fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital